On June 1, 2026, a new publication regarding plecanatide appeared in the European Journal of Gastroenterology & Hepatology. The paper, titled "Efficacy and tolerability of plecanatide for irritable bowel syndrome with constipation and chronic idiopathic constipation: a systematic review and meta-analysis," was released in the journal. This publication is a systematic review and meta-analysis examining plecanatide in the context of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Plecanatide is an approved compound. No specific findings, effect sizes, or conclusions from the study have been provided beyond the title and journal listing. Readers interested in the specifics of the reported efficacy and tolerability data should consult the full publication directly through the source link. For general background on plecanatide, including its approved indications and mechanism, readers can refer to the compound overview.
Plecanatide Meta-Analysis on IBS-C and CIC Published
See the full plecanatide overview
Source: https://pubmed.ncbi.nlm.nih.gov/41604554/